Table 1.
Demographic and clinical features of patients with ankylosing spondylitis
| Variable | All patients (n = 616) |
|---|---|
| Male, n (%) | 468 (76.0) |
| Age, years | 41.8 ± 14.2 |
| Duration of AS, years | 10.0 (5.0, 19.0) |
| Peripheral arthritis, n (%) | 300 (48.7) |
| IBD, n (%) | 23 (3.7) |
| Uveitis, n (%) | 68 (11.0) |
| Hyperuricemia, n (%) | 119 (19.3) |
| Diabetes mellitus, n (%) | 53 (8.6) |
| Hypertension, n (%) | 138 (22.4) |
| Kidney stone, n (%) | 24 (3.9) |
| Medication for AS | |
| NSAIDs, n (%) | 323 (52.4) |
| DMARDs, n (%) | 270 (43.8) |
| Anti-TNFs, n (%) | 72 (11.7) |
| BMI, kg/m2 | 23.5 ± 4.4 |
| Systolic BP, mmHg | 125.2 ± 18.2 |
| Diastolic BP, mmHg | 77.2 ± 11.9 |
| Albumin, g/L | 40.0 ± 5.7 |
| Total cholesterol, mmol/L | 4.3 ± 1.3 |
| Triglyceride, mmol/L | 1.3 (0.8, 1.6) |
| Uric acid, μmol/L | 336.1 ± 111.3 |
| ESR, mm/h | 19.0 (12.0, 34.0) |
| CRP, mg/dL | 10.2 (3.1, 28.1) |
| Serum creatinine, μmol/L | 67.0 (57.0, 77.0) |
| eGFR, mL/min/1.73 m2 | 106.8 ± 22.5 |
| HLA-B27 positive, n (%) | 539 (87.5) |
Abbreviations: AS ankylosing spondylitis, IBD inflammatory bowel disease, NSAIDs non-steroidal anti-inflammatory drugs, DMARDs disease-modifying anti-rheumatic drugs, TNF tumor necrosis factor, BMI body mass index, BP blood pressure, ALT alanine transaminase, ESR erythrocyte sedimentation rate, CRP C-reactive protein, eGFR estimated glomerular filtration rate, HLA-B27 human leukocyte antigen B27